Endoter

Company Overview

Snapshot

Founded in September 2025, Endoter operates with 1–10 employees. The company is currently in its Pre-Funding stage, focusing on the development of innovative pain management solutions.

Business overview

Endoter, also known as EndorTech, is an Israeli healthtech startup developing synthetic biological beta-endorphin formulations delivered via aerosol. The company aims to provide potent, targeted pain relief as a natural alternative to opioid painkillers, with a focus on reducing side effects and offering competitive costs. Endoter's technology is designed to replace conventional opioid-based therapies across multiple clinical settings, leveraging expertise in neuroscience, biopharma, and medical device development to advance next-generation pain management solutions.

Company Intelligence Q&A

What is Endoter's primary focus?

Endoter is focused on developing synthetic biological beta-endorphin formulations delivered via aerosol to provide non-opioid pain relief. The company aims to offer a natural alternative to conventional opioid-based therapies.

When was Endoter founded?

Endoter was founded in September 2025.

What problem is Endoter trying to solve?

Endoter is addressing the need for potent, targeted pain relief with fewer side effects and competitive costs, aiming to replace conventional opioid-based therapies that often carry significant risks.

What is Endoter's current product stage?

Endoter is currently in the R&D stage, working on designing protected delivery systems and advancing its pain management solutions.

Where is Endoter headquartered?

Endoter is headquartered in Tel Aviv-Yafo, Israel.